ARTICLE | Clinical News
SGX203: Preliminary Phase I data
July 15, 2013 7:00 AM UTC
Preliminary data from the Phase I BDP-PCD-01 trial in 24 healthy volunteers ages 18-22 years showed that 6 mg oral twice-daily SGX203 for 7 days was well tolerated. The company plans to start a Phase ...